|
|
On February 3, 2015, the U.S. Food and Drug Administration (FDA) approved a new drug for the treatment of ER+ (Estrogen-Receptor positive) and HER2- (Human Epidermal Growth Factor Receptor 2 –negative) breast cancers. The drug, called Ibrance (palbociclib) was granted FDA approval through the agency’s accelerated approval program, based on promising results from a Phase . . . → Read More: FDA Approves New Breast Cancer Drug
In a large portion of human breast cancers, cancer growth is closely linked to the amount of estrogen in the body. For all intents and purposes, estrogen fuels growth in these Estrogen Receptor Positive (ER+) Cancers. However, a group of researchers recently discovered that another common molecule may play a similar role. When the body . . . → Read More: Cholesterol Molecule Influences Growth of ER+ Cancers
Bisphenol-A (BPA) is a chemical used in a variety of everyday consumer products, including bicycle helmets, the plastics used to manufacture water bottles, baby bottles and utensils and the linings of many food cans. For more than a decade scientific evidence has accumulated to suggest that exposure to BPA, a chemical that is useful as . . . → Read More: Prenatal and Postnatal BPA Exposure
Contralateral prophylactic mastectomy (CPM) is a procedure in which a woman with breast cancer in one breast has both the affected breast and the healthy breast removed at the same time. Between 1998 and 2008, CPM procedures increased 15 percent per year among breast cancer patients in the United States. While removing a healthy breast . . . → Read More: Choosing Contralateral Mastectomy
When researchers look at data on survival rates between black and white women diagnosed with breast cancer, they find a rather significant disparity. White women tend to live longer after diagnosis than do black women. Racial disparities in cancer survival have been acknowledged for some time, though it is recognized that the reasons for this . . . → Read More: Breast Cancer Survival Disparities
For many years, researchers have explored possible “biomarkers” for breast cancer. These are molecules that would allow clinicians to easily test for breast cancer with non-invasive, less costly diagnostic tests. In addition to diagnostics, the identification of certain biomarkers (e.g. Her2Neu) has revealed different types of breast cancer that have significantly better or worse outcomes. . . . → Read More: Future Blood Test for Breast Cancer? |
|
| Copyright © 2021 Breast Cancer Consortium – Archives - All Rights Reserved. Privacy Policy |